Pedoman Tatalaksana Dislipidemia PERKI 2013

  • Erwinanto E JKI
  • Anwar santoso JKI
  • Johannes NE Putranto JKI
  • Pradana Tedjasukmana JKI
  • Rurus Suryawan JKI
  • Sodiqur Rifqi JKI
  • Sutomo Kasiman JKI

Abstract

Pedoman tatalaksana ini merupakan pedomantatalaksana dislipidemia pertama yang dibuat olehPERKI. Tujuan pembuatan pedoman tatalaksana iniadalah untuk membantu dokter membuat keputusandalam praktek sehari-hari. Pedoman inimenyarikandan mengevaluasi bukti-bukti yang ada ketikapedoman tatalaksana ini dibuat. Isi dari pedomantatalaksana ini mengacu terutama pada pedomantatalaksana dislipidemia ESC/EAS tahun 2011 sertaberbagai hasil penelitian lainnya. Keputusan akhirtentang terapi individual merupakan tanggung jawabdari dokter yang menangani pasien.

Downloads

Download data is not yet available.

References

WHO. World Health Stastistics. 2007.

Hokanson J E, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a metaanalysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-9.

Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber

TR. High Density Lipoprotein As a Protective Factor Against

Coronary Heart Disease. The Framingham Study. Am J Med

;62:707-14.

Karthikeyan G, Teo KK, Islam S, McQueen MJ, Pais P, Wang

X, Sato H, Lang CC, Sitthi-Amorn C, Pandey MR, Kazmi K,

Sanderson JE, Yusuf S. Lipid Profile, Plasma polipoproteins,

and Risk of a First Myocardial Infarction Among Asians: An

Analysis From the INTERHEART Study. J Am Coll Cardiol

;53:244-53.

Asia Pacific Cohort Studies Collaboration. Cholesterol, Coronary Heart Disease and Stroke in the Asia Pacific Region. Int J Epidemiol 2003;32:563-72.

Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F,

McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART

Study Investigators. Effect of potentially modifiable

risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case-control study. Lancet

;364:937-52.

Tim Biomedis Riset Kesehatan Dasar, Badan Penelitian dan

Pengembangan Kesehatan Kementrian Kesehatan Republik

Indonesia. Laporan Riset Kesehatan Dasar (Riskesdas) Bidang

Biomedis. 2010:20-5.

Steg P G, Bhatt DL, Wilson PW, D’Agostino R Sr, Ohman

EM, Röther J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina

MJ, Goto S; REACH Registry Investigators. One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis.JAMA 2007;297.

Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170000 participants in 26 randomised trials. Lancet 2010;376:1670-81.

Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC. Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol,and cardiovascular events. N Engl J Med 2007;357:1301-10.

Rubins H B, Robins SJ, Collins D, Fye CL, Anderson JW,

Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G,

Wilt TJ, Wiites J. Veterans Affairs High-Density Lipoprotein

Cholesterol Intervention Trial Study Group. Gemfibrozil for

the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-8.

Barter P J, Caulfield M, Eriksson M, Grundy SM, Kastelein JP, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD,

Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B.

ILLUMINATE investigators. Effects of torcetrapib in patients

at high risk for coronary events. N Engl J Med 2007;357:2109- 22.

The AIM-HIGH Investigators. Niacin in Patients with Low

HDL Cholesterol Levels Receiving Intensive Statin Therapy.

N Engl J Med 2011;365:2255-67.

HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized

placebo-controlled trial in 25 673 high-risk patients

of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34:1279-91.

Triglyceride Coronary Disease Genetics Consortium and

Emerging Risk Factors Collaboration, Sarwar N, Sandhu MS,

Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt

SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, Lawlor

D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J. Triglyceridemediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010;375:1634-9.

Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007;298:309-16.

Nordestgaard B G, Benn M, Schnohr P, Tybjaerg-Hansen A.

Nonfasting triglycerides and risk of myocardial infarction,

ischemic heart disease, and death in men and women. JAMA

;298:299-308.

Pischon T, Giran CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non–high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.Circulation 2005;112:3375-83.

Jurnal Kardiologi Indonesia 264 Jurnal Kardiologi Indonesia • Vol. 34, No. 4 • Oktober - Desember 2013

Ridker P M, Rifai N, Cook NR, Bradwin G, Buring JE. Non-

HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005;294:326-33.

Sniderman A D, Furberg CD, Keech A, Roeters van Lennep

JE, Frohlich J, Jungner I, Walldius G. Apolipoprotein versus

lipids as indices of coronary risk and as targets for statin therapy treatment. Lancet 2003;361:777-80.

Robinson J G, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein reduction and coronary heart disease risk. J Am Coll Cardiol 2009;53:316-22.

The Emerging Risk Factors Collaboration. Major lipids apolipoproteins,and risk of vascular disease. JAMA 2009;302:1993-2000.

Grundy S M, Becker D, Clark LT, Cooper RS, Denke MA,

Howard WmJ, Hunninghake DB, Illingworth DR, Luepker

RV, McBride P, McKenney JM, Pasternak RC, Stone NJ, Horn

LV. National Cholesterol Education Program (NCEP) Expert

Panel on Detection Evaluation and Treatment of High Blood

Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP)

Expert Panel on Detection, Evaluation, and Treatment of High

Blood Cholesterol in Adults (Adult Treatment Panel III): Final Report. Washington, DC: National Institutes of Health, Heart, Lung,nd Blood Institute 2002;NIH Publication

No.02:5215.

Taskinen M R, Barter PJ, Ehnholm C, Sullivan DR, Mann

K, Simes J, Best JD, Hamwood S, Keech AC on behalf of the

FIELD Study Investigators. Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. Diabetologia 2010;53:1846-55.

Erqou S, Kaptoge S, Perry PL, Di AE, Thompson A, White

IR, Marcovina SM, Collins R, Thompson SG, Danesh J.

Lipoprotein(a) concentration and the risk of coronary heart

disease, stroke, and nonvascular mortality. JAMA 2009;302:412-23.

Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de FU, Seedorf U, Hamsten A, Collins R, Watkins H, Farrall M. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009;361:2518-28.

Greene D J, Skeggs JW, Morton RE. Elevated triglyceride

content diminishes the capacity of high density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type I (SR-BI). J Biol Chem 2001;276:4804-11.

Skeggs J W, Morton RE. LDL and HDL enriched in triglyceride promote abnormal cholesterol transport. J Lipid Res 2002;43:1264-74.

Chait A, Brazg RL, Tribble DL, Krauss RM. rusceptibility of

small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993;94:350-6.

Kwiterovich P OJ. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. Am J Cardiol 2002;90.

Ip S, Lichtenstein AH, Chung M, Lau J, Balk EM. Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes. Ann Intern Med 2009;150:474-84.

Friedewald W T, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma,without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.

Conroy R, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetie`re P, Jousilahti P, Keil U,Njølstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham I. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003.

D’Agostino R BS, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743-53.

Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P,Erdine S, Halcox J, Hobbs R, JKjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D for The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC)and the European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2011;32:1769-818.

Grundy S M, Cleeman JI, Merz CN, Brewer HB Jr, Clark

LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ;

for the Coordinating Committee of the National Cholesterol

Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39, 763 (correction).

Law M R, Wald NJ, Thompson SG. By how much and how

quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994;308:367-72.

Law M R. Lowering heart disease risk with cholesterol reduction: evidence from observational studies and clinical trials. Eur Heart J Suppl 1999;Suppl S:S3-S8.

Lipid Research Clinics Program Epidemiology Committee.

Plasma lipid distributions in selected North American populations:the Lipid Research Clinics Program Prevalence Study.Circulation 1979;60:427-39.

Nordestgaard B G, Chapman J, Ray K, Bore´n J, Andreotti F,Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps

Erwinanto dkk: Pedoman tatalaksana dislipidemia

Jurnal Kardiologi Indonesia • Vol. 34, No. 4 • Oktober - Desember 2013 265 OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgo¨zoglu L, Tybjærg-Hansen A, for the European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31:2844-53.

Mora S, Szklo M, Otvos JD, Greenland P, Psaty BM, Goff DC Jr, O’Leary DH, Saad MF, Tsai MY, Sharrett AR. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of therosclerosis (MESA). Atherosclerosis 2007;192:211-7.

Jones P H, Davidson MH, Stein EA, Bays HE, McKenney

JM, Miller E, Cain VA, Blasetto JW. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003;92:152-60.

The BIP Study Group. Secondary prevention by raising HDL

cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP)Study. Circulation 2000;102:21-7.

Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesa¨niemi YA, Sullivan D, Hunt D, Colman P, d’Emden M, Whiting M,Ehnholm C, Laakso M. The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.

Jun M, Foote C, Lu J, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic V. Effects of fibrates on cardiovascular

outcomes: a systematic review and meta-analysis. Lancet

;375:1875-84.

Jones P H, Davidson MH. Reporting rate of rhabdomyolysis

with fenofibrate+statin versus gemfibrozil+any statin. Am J

Cardiol 2005;95:120-2.

Ford E S, Ajani UA, Croft JB, Critchley JA, Labarthe DR,

Kottke TE, Giles WH, Capewell S. Explaining the decrease in

U.S. deaths from coronary disease, 1980-2000. N Engl J Med

;356:2388-98.

Mensink R P, Zock PL, Kester ADM, Katan MB. Effects of

dietary fatty acids and carbohydrates on the ratio of serum

total to HDL cholesterol and on serum lipids and apolipoproteins:

a meta-analysis of 60 controlled trials. Am j Clin Nutr

;77:1146-55.

Harris W S. Omega-6 Fatty Acids and Risk for Cardiovascular

Disease : A Science Advisory From the American Heart Association

Nutrition Subcommittee of the Council on Nutrition,

Physical Activity, and Metabolism. Circulation 2009;119:902-

Denmacker P N, Reijnen IG, Katan MB, Stuyt PM, Stalenhoef

AF. Increased removal of remnants of triglyceride-rich lipoproteins

on a diet rich in polyunsaturated fatty acids. Eur J Clin

Invest 1991;21:197-203.

Zheng C, Khoo C, Furtado J, Ikewaki K, Sacks FM. Dietary

monounsaturated fat activates metabolic pathways for triglyceride-

rich lipoproteins that involve apolipoproteins E and C-III.

Am j Clin Nutr 2008;99:272-81.

Lichtenstein A H, Ausman LM, Jalbert SM, Schaefer EJ. Effects

of different forms of dietary hydrogenated fats on serum lipoprotein

cholesterol levels. N Engl J Med 1999;340:1933-40.

Katan M B, Zock PL, Mensink RP. Trans fatty acids and their

effects on lipoproteins in humans. Ann Rev Nutr 1995;15:473-

Ascherio A, Katan MB, Zock PL, Stampfer MJ, Willett WC.

Trans fatty acids and coronary heart disease. N Engl J Med

;340:1994-8.55. NCEP Expert Panel on detection evaluation and treatment of

high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.

Brown L, Rosner B, Willet W, Sacks SM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr 1999;69:30-42.

Kodama S, Tanaka S, Saito K, Shu M, Sone Y, Onitake F, Suzuki E, Shimano H, Yamamoto S, Kondo K, Ohashi Y, Yamada N,Sone H. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch Intern Med 2007;167:999-1008.

Magkos F, Tsekouras YE, Prentzas KI, Basioukas KN, Matsama SG, Yanni AE, Kavouras SA, Sidossis LS. Acute exercise-induced changes in basal VLDL-triglyceride kinetics leading to hypotriglyceridemia

manifest more readily after resistance than

endurance exercise. J Appl Physiol 2008;105:1228-36.

Tambalis K, Panagiotakos DB, Kavouras SA, Sidossis LS.

Responses of blood lipids to aerobic, resistance, and combined aerobic with resistance exercise training: a systematic review of current evidence. Angiology 2009;60:614-32.60. Kelley G A, Kelley KS. Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-analysis of randomized

controlled trials. Prev Med 2009;48:9-19.

Couillard C, Despre´s JP, Lamarche B, Bergeron J, Gagnon J,Leon AS, Rao DC, Skinner JS, Wilmore JH, Bouchard C. Effects of endurance exercise training on plasma HDL cholesterol levels depend on levels of triglycerides: evidence from men of the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family Study. Arterioscler Thromb Vasc Biol 2001;21:1226-32.

Kraus W E, Houmard JA, Duscha BD, Knetzger KJ, Wharton

MB,, McCartney JS BC, Henes S, Samsa GP, Otvos JD,

Kulkarni KR, Slentz C. Effects of the amount and intensity of Jurnal Kardiologi Indonesia

Jurnal Kardiologi Indonesia • Vol. 34, No. 4 • Oktober - Desember 2013 exercise on plasma lipoproteins. N Engl J Med 2002;347:1483-92.

Duncan G E, Anton SD, Sydeman SJ, Newton RL Jr, Corsica

JA, Durning PE, Ketterson TU, Martin AD, Limacher MC,

Perri MG. Prescribing exercise at varied levels of intensity and frequency: a randomized trial. Arch Intern Med 2005;165:2362- 9.

Durstine J L, Summer AC. Physical Activity, Exercise, Blood Lipids, and Lipoproteins. In Moffatt JR, Stamford B, Eds. Lipid Metabolism and Health. Boca Raton: CRC Press 2006.65. Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, Van der Schouw YT, Spencer E, Moons

KGM, Tjønneland A, Halkjaer J, Jensen MK, Stegger J, Clavel-

Chapelon F, Boutron-Ruault MC, Chajes V, Linseisen J, Kaaks

R, Trichopoulou A, Trichopoulos D, Barnia C, Sieri S, Palli D,Tumino R, Vineis P, Panico S, Peeters PHM, May AM, Buenode- Mesquita HB, van Duijnhoven FJB, Hallmans G, Weinehall L, Manjer J, Hedblad B, Lund E, Agudo A, Arriola L, Barricarte

A, Navarro C, Martinez C, Quirós JR, Key T, Bingham S,

Khaw KT, Boffetta P, Jenab M, Ferrari P, Riboli E. General and Abdominal Adiposity and Risk of Death in Europe. N Engl J Med 2008;359:2105-20. 66. Inoue S. The Asia-Pacific Perspective: Redefining Obesity and

Its Treatment. WHO International Obesity Task Force 2000.

Prospective study collaboration. Body-mass index and causespecific mortality in 900000 adults: collaborative analyses of 57 prospective studies. Lancet 2009;373.

Dattilo A M, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am j Clin Nutr 1992;56:320-8.

The Look AHEAD Research Group. Cardiovascular Effects of

Intensive Lifestyle Intervention in Type 2 Diabetes. N Engl J Med 2013. 70. Maeda K, Noguchi Y, Fukui T. The effects of cessation from

cigarette smoking on the lipid and lipoprotein profiles: a metaanalysis.

Prev Med 2003;37:283-90.

Stone N J. Secondary causes of hyperlipidemia. Med Clin North

Am 1994;78:117-41.

Chait A, Brunzell JD. Acquired hyperlipidemia (secondary

dyslipoproteinemias). Endocrinol Metab Clin North Am

;19:259-78.

Hendriks H F, Weststrate JA, van Vliet T, Meijer GW. Spreads

enriched with three different levels of vegetable oil sterols and

the degree of cholesterol lowering in normocholesterolaemic

and mildly hypercholesterolaemic subjects. Eur J Clin Nutr

;53:319-27.

Katan M B, Grundy SM, Jones P, Law M, Miettinen T, Paoletti

R. Efficacy and safety of plant stanols and sterols in the management

of blood cholesterol levels. Mayo Clin Proc 2003;78:965-

Abumweis S S, Barake R, Jones PJ. Plant sterols/stanols as

cholesterol lowering agents: a meta-analysis of randomized

controlled trials. Food Nutr Res 2008;52.

Dewell A, Hollenbeck PL, Hollenbeck CB. A critical evaluation

of the role of soy protein and isoflavone supplementation in the

control of plasma cholesterol concentrations. J Clin Endocrinol

Metab 2006;91:772-80.

Jenkins D J, Kendall CW, Vidgen E, Mehling CC, Parker T,

Seyler H, Faulkner D, Garsetti M, Griffin LC, Agarwal S, Rao

AV, Cunnane SC, Ryan MA, Connelly PW, Leiter LA, Vuksan

V, Josse R. The effect on serum lipids and oxidized low-density

lipoprotein of supplementing self-selected low-fat diets with

soluble fiber, soy, and vegetable protein foods. Metabolism

;49:67-72.

U.S. Department of Health and Human Services. Food and

Drug Administration. Food labeling: health claims; soluble

fiber from certain foods and coronary heart disease: final rule.

Federal Register 1998;63:8103-21.

U.S. Department of Health and Human Services. Food and

Drug Administration. Food labeling: health claims; soluble fiber

from certain foods and coronary heart disease: proposed rule.

Federal Register 1997;62:28234-45.

Rideout T C, Harding SV, Jones PJ, Fan MZ. Guar gum and

similar soluble fibers in the regulation of cholesterol metabolism:

current understandings and future research priorities. Vasc

Health Risk Manag 2008;4:1023-33.

Harris W S. n-3 Fatty acids and serum lipoproteins: human

studies. Am j Clin Nutr 1997;65 (suppl.):1645S-54S.

Prasad K. Flaxseed and cardivascular health. J Cardiovasc Pharmacol

;54:369-77.

Kromhout D, Giltay EJ, Geleijnse JM for the Alpha Omega

Trial Group. n-3 Fatty acids and cardiovascular events after

myocardial infarction. N Engl J Med 2010;363:2015-26.

Hooper L, Thompson RL, Harrison RA, Summerbell CD, Ness

AR, Moore HJ, Worthington HV, Durrington PN, Higgins JPT,

Capps NE, Riemersma RA, Ebrahim SBJ, Davey Smith G. Risks

and benefits of omega 3 fats for mortality, cardiovascular disease,

and cancer: systematic review. BMJ 2006;332:752-60.

Yokoyama M OH, Matsuzaki M, Matsuzawa Y, Saito Y, Oikawa

S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya

N, Sakata T, Shimada K, Shirato K. Effects of eicosapentaenoic

acid on major coronary events in hypercholesterolaemic patients

(JELIS): a randomised openlabel, blinded endpoint analysis.

Lancet 2007;369:1090-8.

Endo A. The discovery and development of HMG-CoA reductase

inhibitors. J Lipid Res 1992;33:1569-82.

Bilheimer D W, Grundy SM, Brown MS, Goldstein JL. Mevinolin

and colestipol stimulate receptor-mediated clearance of low

density lipoprotein from plasma in familial hypercholesterolemia

heterozygotes. Proc Natl Acad Sci USA 1983;80:4124-8.

Erwinanto dkk: Pedoman tatalaksana dislipidemia

Jurnal Kardiologi Indonesia • Vol. 34, No. 4 • Oktober - Desember 2013 267

Barter P J, Brandrup-Wognsen G , Palmer MK, Nicholls SJ.

Effect of statins on HDL-C: a complex process unrelated to

changes in LDL-C: analysis of the VOYAGER Database. J Lipid

Res 2010;51:1546-53.

Long-Term Intervention with Pravastatin in Ischaemic Disease

(LIPID) Study Group. Prevention of cardiovascular events and

death with pravastatin in patients with coronary heart disease

and a broad range of initial cholesterol levels. N Engl J Med

;339:1349-57.

Downs J R, Clearfield M, Weis S, Whitney E, Shapiro DR,

Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr,

for the AFCAPS/TexCAPS Research Group. Primary prevention

of acute coronary events with lovastatin in men and women with

average cholesterol levels: results of AFCAPS/TexCAPS. JAMA

;279:1615-22.

Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane

PW, McKillop JH, Packard CJ, for the West of Scotland

Coronary Prevention Study Group. Prevention of coronary heart

disease with pravastatin in men with hypercholesterolemia. N

Engl J Med 1995;333:1301-7.

Scandinavian Simvastatin Survival Study Group. Randomised

trial of cholesterol lowering in 4444 patients with coronary

heart disease: the Scandinavian Simvastatin Survival Study (4S).

Lancet 1994;344:1383-9.

Sacks F M, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD,

Cole TG, Brown L, Warnica JW,Arnold JMO, Wun C-C, Davis

BR, Braunwald E, for the Cholesterol and Recurrent Events Trial

Investigators. The effect of pravastatin on coronary events after

myocardial infarction in patients with average cholesterol levels.

N Engl J Med 1996;335:1001-9.

U.S. Department of Health and Human Services. Food and

Drug Administration. FDA Drug Safety Communication: New

restrictions, contraindications, and dose limitations for Zocor

(simvastatin) to reduce the risk of muscle injury. 2011.

Nelson R G, Tuttle KR, Bilous RW, Gonzalez-CampoyJM,

Mauer M, Molitch ME, Sharma K, Judith Fradkin E, Narva AS.

KDOQI Clinical Practice Guideline For Diabetes and CKD:

Update. Am J Kidney Dis 2012;60:850-86.

Tyroler H A. Cholesterol and cardiovascular disease. An overview

of Lipid Research Clinics (LRC) epidemiologic studies as

background for the LRC Coronary Primary Prevention Trial.

Am J Cardiol 1984;54:14C-9C.

Canner P L, Berge KG, Wenger NK, Stamler J, Friedman L,

Prineas RJ, Friedewald W. Fifteen year mortality in Coronary

Drug Project patients: longterm benefit with niacin. J Am Coll

Cardiol 1986;8:1245-55.

Pasternak R C, Smith Jr SC, Bairey-Merz CN, Grundy SM, Cleeman

JI, Lenfant C. ACC/AHA/NHLBI Clinical Advisory on

the Use and Safety of Statins. J Am Coll Cardiol 2002;40:567-

Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the

safety and efficacy of HMG-CoA reductase inhibitor monotherapy

in the treatment of primary hypercholesterolemia. Ann

Pharmacother 1995;29:743-59.

U.S. Department of Health and Human Services. Food and

Drug Administration. Statin Drugs - Drug Safety Communication:

Class Labeling Change. 2012.

Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen

AJ, Seshasai SR,McMurray JJ, Freeman DJ, Jukema JW, Macfarlane

PW, Packard CJ, Stott DJ,Westendorp RG, Shepherd J,

Davis BR, Pressel SL, Marchioli R, Marfisi RM,Maggioni AP,

Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ,Gotto

AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno

K,Ray KK, Ford I. Statins and risk of incident diabetes: a

collaborative meta-analysis of randomized statin trials. Lancet

:735-42.

Ford I, Murray H, Packard CJ, Shepherd J, McFarlane PW,

Cobbe SM, for the West of Scotland Coronary Prevention Study

Group. Long-Term Follow-up of the West of Scotland Coronary

Prevention Study. N Engl J Med 2007;357:1477-86.

Reckless JP D, Henry P, Pomykaj T, Lim ST, Massaad R,

Vandormael K, Johnson-Levonas AO, Lis K, Brudi P, Allen C.

Lipid-altering efficacy of ezetimibe?simvastatin 10?40 mg compared

with doubling the statin dose in patients admitted to the

hospital for a recent coronary event: the INFORCE study. Int

J Clin Pract 2008;62:539-54.

Rossebø A B, Pedersen TR, Boman K, Brudi P, Chambers JB,

Egstrup K, Gerdts E, Gohlke-Ba¨rwolf C, Holme I, Kesa¨niemi

YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K,

Willenheimer R. SEAS Investigators. Intensive lipid lowering

with simvastatin and ezetimibe in aortic stenosis. N Engl J Med

;359:1343-56.

SHARP Collaborative Group. Study of Heart and Renal Protection

(SHARP): randomized trial to assess the effects of lowering

low-density lipoprotein cholesterol among 9,438 patients with

chronic kidney disease. Am Heart J 2010;160:785-94.

Florentin M, Liberopoulos EN, Elisaf MS. Ezetimibe-associated

adverse effects: what the clinician needs to know. Int J Clin Pract

;62:88-96.

Peto R, Emberson J, Landray M, Baigent C, Collins R, Clare R,

Califf R. Analyses of Cancer Data from Three Ezetimibe Trials.

N Engl J Med 2008;359:1357-66.

Cannon C P, Giugliano RP, Blazing MA, Harrington RA, Peterson

JL, Sisk CMC, Strony J, Musliner TA, McCabe CH, Veltri

E, Braunwald E, Califf RM, for the IMPROVE-IT Investigators.

Rationale and design of IMPROVE-IT (IMProved Reduction

of Outcomes: Vytorin Efficacy International Trial): Comparison

of ezetimbe/simvastatin versus simvastatin monotherapy

on cardiovascular outcomes in patients with acute coronary

syndromes. Am Heart J 2008;156:826-32.

Jurnal Kardiologi Indonesia

Jurnal Kardiologi Indonesia • Vol. 34, No. 4 • Oktober - Desember 2013

Knopp R H. Drug treatment of lipid disorders. N Engl J Med

;341:498-511.

The ACCORD Study Group. Effects of combination lipid therapy

in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-

Davidson M H, Armani A, McKenney JM, Jacobson TA. Safety

considerations with fibrate therapy. Am J Cardiol 2007;99:3C-

C.

Knopp R H, Ginsberg J, Albers JJ, Hoff C, Ogilvie JT, Warnick

GR, Burrows E, Retzlaff B, Poole M. Contrasting effects of

unmodified and time-release forms of niacin on lipoproteins in

hyperlipidemic subjects: clues to mechanism of action of niacin.

Metabolism 1985;34:642-50.

Grundy S M, Mok HYI, Zech L, Berman M. Influence of

nicotinic acid on metabolism of cholesterol and triglycerides

in man. J Lipid Res 1981;22:24-36.

Knopp R H, Alagona P, Davidson M, Goldberg AC, Kafonek

SD, Kashyap M, Sprecher D, Superko HR, Jenkins S, Marcovina

S. Equivalent efficacy of a time-release form of niacin (Niaspan)

given once-a-night vs. plain niacin in the management of hyperlipidemia.

Metabolism 1998;47:1097-104.

Kamanna V S, Kashyap ML. Mechanism of action of niacin.

Am J Cardiol 2008;101:20B-6B.

Thrive Study. http://www.thrivestudy.org/press_release.htm.

Barter P J, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader

DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for

raising HDL and inhibiting atherosclerosis. Arterioscler Thromb

Vasc Biol 2003;23:160-7.

Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney

JM, Littlejohn III TW, III, Sisk CM, Mitchel Y, Pasternak

RC. Efficacy and safety of the cholesteryl ester transfer protein

inhibitor anacetrapib as monotherapy and coadministered with

atorvastatin in dyslipidemic patients. Am Heart J 2009;157:352-

e2.

Reiner Z. Combined therapy in the treatment of dyslipidemia.

Fundam Clin Pharmacol 2010;24:19-28.

Huijgen R, Abbink EJ, Bruckert E, Stalenhoef AF, Imholz BP,

Durrington PN, Trip MD, Eriksson M, Visseren FL, Schaefer

JR, Kastelein JJ; Triple Study Group. Colesevelam added to

combination therapy with a statin and ezetimibe in patients with

familial hypercholesterolemia: a 12-week multicenter, randomized,

double-blind, controlled trial. Clin Ther 2010;32:615-

Grundy S M, Vega GL, Yuan Z, Battisti WP, Brady WE,

Palmisano J. Effectiveness and tolerability of simvastatin plus

fenofibrate for combined hyperlipidaemia (the SAFARI trial).

Am J Cardiol 2005;95:462-8.

McKenney J M, Jones PH, Bays HE, Knopp RH, Kashyap

ML, Ruoff GE, McGovern ME. Comparative effects on lipid

levels of combination therapy with a statin and extended-release

niacin or ezetimibe versus a statin alone (the COMPELL study).

Atherosclerosis 2007;192:432-7.

DeMott K, Nherera L, Shaw EJ, Minhas R, Humphries SE,

Kathoria M, Ritchie G,Nunes V, Davies D, Lee P, McDowell I,

Neil A, Qureshi N, Rowlands P, Seed M, Stracey H, Thorogood

M, Watson M. . Clinical guidelines and evidence review for

familial hypercholesterolaemia: the identification and management

of adults and children with familial hypercholesterolaemia.

National Collaborating Centre for Primary Care and Royal

College of General Practitioners 2008.

Veenkamp M S, de Graaf J, Bredie SJ, Hendriks JC, Demacker

PN, Stalenhoef AF. . Diagnosis of familial combined hyperlipidemia

based on lipid phenotype expression in 32 families:

results of a 5-year follow-up study. Arterioscler Thromb Vasc

Biol 2002;22:274-82.

Gaddi A, Cicero AFG, Odoo FO, Poli AA, Paoletti R. Practical

guidelines for familial combined hyperlipidemia diagnosis: an

up-date. . Vasc Health Risk Manag 2007;3:877-86.

Kostis W J, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB.

. Meta-Analysis of Statin Effects in Women Versus Men. J Am

Coll Cardiol 2012;59:572-82.

Lewis S J, Moye LA, Sacks FM, Johnstone DE, Timmis G,

Mitchell J, Limacher M, Kell S, Glasser SP, Grant J, Davis BR,

Pfeffer MA, Braunwald E. for the CARE investigators Effect

of pravastatin on cardiovascular events in older patients with

myocardial infarction and cholesterol levels in the average range.

Ann Intern Med 1998;129:681-9.

Miettinen T A, Pyörälä K, Olsson AG, Musliner TA, Cook

TJ, Faergeman O, Berg K, Pedersen T, Kjekshus J. Cholesterol

lowering therapy in women and elderly patients with myocardial

infarction or angina pectoris: findings from the Scandinavian

Simvastatin Survival Study (4S). Circulation 1997;96:4211-8.

Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM,

Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper

AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ,

Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG;

PROSPER Study Group. . PROspective Study of Pravastatin

in the Elderly at Risk. Pravastatin in elderly individuals at risk

of vascular disease (PROSPER): a randomised controlled trial.

Lancet 2002;360:1623-30.

Alberti K G, Eckel RH, Grundy SM, Zimmet PZ, Cleeman

JI, Doanto KA, Fruchart J-C, James PT, Loria CM, Smith SC.

Harmonizing the metabolic syndrome: a joint interim statement

of the International Diabetes Federation Task Force on

Epidemiology and Prevention; National Heart, Lung, and Blood

Institute; American Heart Association; World Heart Federation;

International Atherosclerosis Society; and International Association

for the Study of Obesity. Circulation 2009;120:1640-5.

Hillier T A, Rizzo JH, Pedula KL, Cauley JA, Schwartz AV,

Ensrud KE, Browner WS. . Increased Mortality Associated

Erwinanto dkk: Pedoman tatalaksana dislipidemia

Jurnal Kardiologi Indonesia • Vol. 34, No. 4 • Oktober - Desember 2013 269

With the Metabolic Syndrome in Older Women With Diabetes.

Diabetes Care 2005;28:2258-60.

Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P,

Rinfret S, Schiffrin EL, Eisenberg MJ. . The metabolic syndrome

and cardiovascular risk. A systematic review and meta-analysis.

J Am Coll Cardiol 2010;56:1113-32.

Adiels M, Olofsson S-O, Taskinen M-R, Bore´n J. . Overproduction

of very low-density lipoproteins is the hallmark of the

dyslipidaemia in the metabolic syndrome. Arterioscler Thromb

Vasc Biol 2008;28:1225-36.

Scott R, O’Brien R, Fulcher G, Pardy C, D’Emden M, Tse D,

Taskinen M-R, Ehnholm C, Keech A. . Effects of fenofibrate

treatment on cardiovascular disease risk in 9,795 individuals

with type 2 diabetes and various components of the metabolic

syndrome. Diabetes Care 2009;32:493-8.

IIanne-Parikka P, Eriksson JG, Lindstrom J, Peltonen M, Aunola

S, Hamalainen H, Keinanen-Kiukaanniemi S, Laakso M, Valle

TT, Lahtela J, Uusitupa M, Tuomilehto J. Effect of lifestyle

intervention on the occurrence of metabolic syndrome and its

components in the Finnish diabetes prevention study. Diabetes

Care 2008;31:805-7.

Colhoun H M, Betteridge DJ, Durrington PN, Hitman

GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI,

Charlton-Menys V, Fuller JH; CARDS Investigators. . Primary

prevention of cardiovascular disease with atorvastatin in type

diabetes in the Collaborative Atorvastatin Diabetes Study

(CARDS): multicentre randomised placebo-controlled trial.

Lancet 2004;364:685-96.

Adolescent type 1 Diabetes cardio-renal Interventional Trial

Research Group. Adolescent type 1 Diabetes Cardio-renal

Intervention Trial (AdDIT). . BMC Pediatr 2009;9:79.

Kasiske B, Cosio FG, Beto J, Chavers B, Grimm Jr R, Levin

A, Masri B, Parekh R, Wanner C, Wheeler D, Wilson W. . K/

DOQI Clinical Practice Guidelines for Managing Dyslipidemias

in Chronic Kidney Disease. Am J Kidney Dis 2003;41:S1-

S91.

Fellström B C, Jardine AG, Schmieder RE, Holdaas H, Bannister

K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gönhagen-

Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving

HH, Remuzzi G, Samuelsson O, Sonkodi S,Sci D, Süleymanlar

G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP,

Gottlow M, Johnsson E, Zannad F; AURORA Study Group. .

Rosuvastatin and cardiovascular events in patients undergoing

hemodialysis. N Engl J Med 2009;360:1395-407.

Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf

G, Ritz E; German Diabetes and Dialysis Study Investigators. .

Atorvastatin in patients with type 2 diabetes mellitus undergoing

hemodialysis. N Engl J Med 2005;353:238-48.

National Kidney Foundation. K/DOQI clinical practice guidelines

for chronic kidney disease: Evaluation, classification, and

stratification. Am J Kidney Dis 2002;39:S1-S266.

Benfante R, Yano K, Hwang LJ, Curb JD, Kagan A, Ross W.

. Elevated serum cholesterol is a risk factor for both coronary

heart disease and thromboembolic stroke in Hawaiian Japanese

men. Implications of shared risk. Stroke 1994;25:814-20.

Iso H, Jacobs, Jr. DR, Wentworth D, Neaton JD, Cohen JD. .

Serum Cholesterol Levels and Six-Year Mortality from Stroke in

,977 Men Screened for the Multiple Risk Factor Intervention

Trial. . N Engl J Med 1989;320:904-10.

Engström G, Lind P, Hedblad B, Stavenow L, Janzon L,

Lindgärde F. . Effects of Cholesterol and Inflammation-Sensitive

Plasma Proteins on Incidence of Myocardial Infarction and

Stroke in Men. Circulation 2002;105:2632-7.

Prospective Studies Collaboration. Cholesterol, diastolic blood

pressure, and stroke: 13 000 strokes in 450 000 people in 45

prospective cohorts. Lancet 1995;346:1647-53.

Suh I, Jee SH, Kim HC, Nam CM, Kim IS, Appel LJ. . Low

serum cholesterol and haemorrhagic stroke in men: Korea Medical

Insurance Corporation Study. Lancet 2001;357:922-25.

LaRosa J C, Grundy SM, Waters DD, Shear C, Barter P, Fruchart

JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J,Wenger

NK; Treating to New Targets (TNT) Investigators. . Intensive

lipid lowering with atorvastatin in patients with stable coronary

disease. . N Engl J Med 2005;352:1425-35.

Amarenco P, Labreuche J. Lipid management in the prevention

of stroke: review and updated meta-analysis of statins for stroke

prevention. . Lancet Neurol 2009;8:453-63.

Byington R P, Davis BR, Plehn JF, White HD, Baker J, Cobbe

SM, Shepherd J. Reduction of stroke events with pravastatin:

the Prospective Pravastatin Pooling (PPP) project. . Circulation

;103:387-92.

The Stroke Prevention by Aggressive Reduction in Cholesterol

Levels (SPARCL) Investigators. High-dose atorvastatin after

stroke or transient ischemic attack. N Engl J Med 2006;355:549-

Ray K K, Cannon CP, McCabe CH, Cairns R, Tonkin AM,

Sacks FM, Jackson G, Braunwald E; PROVE IT-TIMI 22

Investigators. Early and late benefits of high dose atorvastatin

in patients with acute coronary syndromes: results from the

PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005;46:1405-

Lee K H, Jeong MH, Kim HM, Ahn Y, Kim JH, Chae SC, Kim

YJ, Hur SH, In Whan Seong IW, Hong TJ, Choi DH, Cho

MC, Kim CJ, Seung KB, Chung WS, Jang YS, MD, Rha SW,

Bae JH, Cho JW, Park SJ, KAMIR (Korea Acute Myocardial

Infarction Registry) Investigators. Benefit of early statin therapy

in patients with acute myocardial infarction who have extremely

low low-density lipoprotein cholesterol. J Am Coll Cardiol

;58:1664-71.

GISSI-Prevenzione Investigators. Dietary supplementation

Jurnal Kardiologi Indonesia

Jurnal Kardiologi Indonesia • Vol. 34, No. 4 • Oktober - Desember 2013

with n-3 polyunsaturated fatty acids and vitamin E after myocardial

infarction: results of the GISSIprevenzione trial. Lancet

;354:447-55.

Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G,

Montinaro A. Efficacy of atorvastatin reload in patients on

chronic statin therapy undergoing percutaneous coronary intervention:

results of the ARMYDA-RECAPTURE (Atorvastatin

for Reduction of MYocardial Damage during Angioplasty)

randomized trial. J Am Coll Cardiol 2009;54:558-65.

Pasceri V, Patti G, Nusca A, Pristipino C, Richich Gi, Di Sciascio

G, on behalf of the ARMYDA Investigators. Randomized Trial

of Atorvastatin for Reduction of Myocardial Damage During

Coronary Intervention Results From the ARMYDA (Atorvastatin

for Reduction of Myocardial Damage during Angioplasty)

Study. Circulation 2004;110:674-8.

Winchester D E, Wen X, Xie L, Bavry AA. Evidence of preprocedural

statin therapy: a meta-analysis of randomized trials.

J Am Coll Cardiol 2010;56:1099-109.

Briguori C, Visconti G, Focaccio A, Golia B, Chieffo A, Castelli

A, Mussardo M, Montorfano M, Ricciardelli B, Colombo A.

Novel approaches for preventing or limiting events (NAPLES)

II trial impact of a single high loading dose of atorvastatin

on periprocedural myocardial infarction. J Am Coll Cardiol

;54:2157-63.

Published
2015-04-01

Abstract viewed :
171 times
PDF downloaded : 662 times

How to Cite
E, E., santoso, A., Putranto, J., Tedjasukmana, P., Suryawan, R., Rifqi, S., & Kasiman, S. (2015). Pedoman Tatalaksana Dislipidemia PERKI 2013. Indonesian Journal of Cardiology, 34(4), 245-70. https://doi.org/10.30701/ijc.v34i4.385
Section
Review Article